Your partner in oncology


Oncology Therapeutic Development

100 rue Martre
92110 Clichy - FRANCE
Tel:  +33 1 47 15 01 01
Fax: +33 1 45 19 06 59

Contact Us


Professor Esteban CVITKOVIC is a medical oncologist specialized in solid tumors and drug development. Prof. Cvitkovic has been instrumental in defining the clinical utility of several oncology drugs contributing to their registration, including cisplatin, oxaliplatin, vinorelbine, irinotecan, docetaxel and trabectedin. He was responsible for leading therapeutic advances in germ cell tumors, squamous head and neck cancer, EBV-related nasopharyngeal carcinoma, soft tissue sarcomas and gastrointestinal cancers.

Prof. Cvitkovic has nearly 50 years of international experience in oncology therapeutics, including hands-on clinical research and pharmacology, disease-oriented therapeutic impact assessment, developing new regimens, evaluating novel agents in preclinical development and optimizing clinical efficacy. He graduated in Argentina as the world's youngest MD at the age of 19, and has held staff and academic appointments at Memorial Sloan Kettering and Columbia Presbyterian (New York, US), Instituto Mario Negri (Milan, Italy), Gustave Roussy, Hôpital Paul Brousse and Hôpital Saint-Louis (France). He has authored more than 250 peer-reviewed articles. 

Career highlights include founding the oncology-focused CRO Cvitovic & Associés Consultants (CAC) in 1996 which was sold to AAIPharma in 2006, and co-founding OncoEthix, a biotechnology company focused on the early development of the first bromodomain inhibitor, sold to Merck in 2014.